-

Kohl's Corporation (KSS) Shareholder Update: Robbins LLP Reminds Investors a Class Action was Filed Against Kohl's Corporation

SAN DIEGO--(BUSINESS WIRE)--The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Kohl's Corporation (NYSE: KSS) securities between October 20, 2020 and May 19, 2022, for violations of the Securities Exchange Act of 1934. Kohl's operates as a retail company in the U.S.

If you would like more information about Kohl's Corporation's misconduct, click here.

What is this Case About: Kohl's Corporation (KSS) Had Deficient Disclosure Controls and Procedures Enabling the Board to Withhold Material Information from Shareholders

According to the complaint, in October 2020, Kohl’s announced that it had entered into a new strategic framework (the "Strategic Plan") to “drive top-line growth,” “expand operating margin,” and become “the most trusted retailer of choice for the active and casual lifestyle.” In addition, Kohl’s announced that the Company was “focused on increasing profitability with a goal of expanding its operating margin to 7% to 8%.” In announcing the Strategic Plan, the Company touted its purportedly strong foundation of customers, industry-leading loyalty and charge card programs, high volume of stores, and large and growing digital business.

On May 19, 2022, Kohl's announced disappointing fiscal Q1 2022 results, which were at odds with defendants' representations regarding the successful execution of the Company's Strategic Plan. Then, on May 20, 2022, Macellum Advisors GP, LLC, "a long-term holder of nearly 5% of the outstanding shares of Kohl's," issued a statement attributing the "extremely disappointing" financial results to a “flawed strategic plan and an inability to execute.” Macellum also stated that “the current Board appears to have withheld material information from shareholders about the state of Kohl’s in the lead-up to this year’s pivotal annual meeting,” which “suggests to us a clear breach of fiduciary duty.” On this news, Kohl’s stock price fell $5.84 per share, or 12.97%, to close at $39.20 per share on May 20, 2022.

Next Steps: If you acquired shares of Kohl's Corporation (KSS) between October 20, 2020 and May 19, 2022, you have until November 1, 2022, to ask the court to appoint you lead plaintiff for the class. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Kohl's Corporation settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:KSS

Release Summary
Kohl's Corporation (KSS) Had Deficient Disclosure Controls and Procedures Enabling the Board to Withhold Material Information from Shareholders
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles
More News From Robbins LLP

Regencell Bioscience Holdings Limited Class Action Reminder - Robbins LLP Encourages RGC Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autis...

POET Technologies Inc. Class Action Reminder - Robbins LLP Encourages POET Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POET Technologies Inc. (NASDAQ: POET) securities between April 1, 2026 and 8:57 A.M. ET on April 27, 2026. POET Technologies describes itself as a "design and development company offering photonic integrated packaging solutions based on the POET Optical Interposer™, a novel platform that allows the seamless integration of electronic and photoni...

Immutep Limited Class Action Reminder - Robbins LLP Encourages IMMP Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug CandidateOn May 5, 2026, a class action was filed on behalf of all investors who purchased or otherwise acquired Immutep Limited American Depository Receipts (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026. Immutep is an Australian-based biotechnology company focused on developing Lymphocyte Activation Gene-3 (LAG-3) related i...
Back to Newsroom